Description
Accession Number: GSE37912
Platform:
GPL5175: [HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version]
Organism: Homo sapiens
Published on 2012-07-01
Summary:
Sarcoidosis, a systemic granulomatous syndrome invariably affecting the lung, typically spontaneously remits but in ~20% of cases progresses with severe lung dysfunction or cardiac and neurologic involvement (complicated sarcoidosis). Unfortunately, current biomarkers fail to distinguish patients with remitting (uncomplicated) sarcoidosis from other fibrotic lung disorders, and fail to identify individuals at risk for complicated sarcoidosis. We utilized genome-wide peripheral blood gene expression analysis to identify a gene signature distinguishing sarcoidosis from healthy controls, which also served as a molecular signature for complicated sarcoidosis.
Overall Design:
Total RNA was isolated from PBMCs using standard molecular biology protocols without DNA contamination or RNA degradation. Sample processing (e.g., cDNA generation, fragmentation, end labeling, hybridization to Affymetrix GeneChip Human Exon 1.0 ST arrays) was performed per manufacturer’s instructions. A total of 29 African descent American (AA) and 10 European descent American (EA) patients with sarcoidosis were included in the overall sarcoidosis cohort with 18 AA and 4 EA patients diagnosed with complicated sarcoidosis.
Contact:
Name: Tong Zhou
Organization: University of Nevada School of Medicine
Address: 1664 N Virginia St Reno NV 89557 USA
Organization: Affymetrix, Inc.
Address: Santa Clara CA 95051 USA
Email: geo@ncbi.nlm.nih.gov, support@affymetrix.com
Phone: 888-362-2447
Web-Link: http://www.affymetrix.com/index.affx
Platform:
GPL5175: [HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version]
Organism: Homo sapiens
Published on 2012-07-01
Summary:
Sarcoidosis, a systemic granulomatous syndrome invariably affecting the lung, typically spontaneously remits but in ~20% of cases progresses with severe lung dysfunction or cardiac and neurologic involvement (complicated sarcoidosis). Unfortunately, current biomarkers fail to distinguish patients with remitting (uncomplicated) sarcoidosis from other fibrotic lung disorders, and fail to identify individuals at risk for complicated sarcoidosis. We utilized genome-wide peripheral blood gene expression analysis to identify a gene signature distinguishing sarcoidosis from healthy controls, which also served as a molecular signature for complicated sarcoidosis.
Overall Design:
Total RNA was isolated from PBMCs using standard molecular biology protocols without DNA contamination or RNA degradation. Sample processing (e.g., cDNA generation, fragmentation, end labeling, hybridization to Affymetrix GeneChip Human Exon 1.0 ST arrays) was performed per manufacturer’s instructions. A total of 29 African descent American (AA) and 10 European descent American (EA) patients with sarcoidosis were included in the overall sarcoidosis cohort with 18 AA and 4 EA patients diagnosed with complicated sarcoidosis.
Contact:
Name: Tong Zhou
Organization: University of Nevada School of Medicine
Address: 1664 N Virginia St Reno NV 89557 USA
Organization: Affymetrix, Inc.
Address: Santa Clara CA 95051 USA
Email: geo@ncbi.nlm.nih.gov, support@affymetrix.com
Phone: 888-362-2447
Web-Link: http://www.affymetrix.com/index.affx
| Date made available | 2012 |
|---|---|
| Publisher | Gene Expression Omnibus |